11-dehydro-thromboxane B2
metaboliteStable metabolite of thromboxane-A2 that quantifies COX-1-dependent platelet activation amplifying thrombosis.
Pathway placement
Cascade stepThromboxane amplification
Confidencehigh
RationaleThromboxane-A2 metabolite; direct marker of COX-1-driven platelet activation.
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I60
C — confounder / Type-II41
A — assay feasibility42
E — evidence strength23
T1DI (composite)6
Specificity differential (R−C)+19.4
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(2)
- Biomarkers of in vivo platelet activation in coronary artery disease: a systematic review and meta-analysis: communication from the SSC of the ISTH.Journal of thrombosis and haemostasis : JTH · 2025 · PMID 40685139 · doi
- Significance of urinary 11-dehydro-thromboxane Bin age-related diseases: Focus on atherothrombosis.Ageing research reviews · 2018 · PMID 30273676 · doi